Madurna and feiser are on tract to bring in more than 53 billion in revenue this year just from the coved vaccines. They're hopeful that m r and a vaccines can be a platform to make vaccines for all sorts of things like cancer and h i v. So therefore, teaching another company how to make an mrnavaccine compromises their hold on the field. None of the companies i spoke to said, this is why. But this is something that people, you know, point out pretty easily.
Less than 1% of those in low income countries are fully vaccinated, and that number only rises to 10% in low-middle income countries. Meanwhile more than half of the population in wealthier countries have received a double dose with several now rolling out third dosess.
In this episode of Coronapod we look at the role of pharmaceutical manufacturers. Drug companies are facing increased pressure to partner with manufacturing firms in the global south but most are reluctant to relinquish control. We ask what needs to change to help address the global disparity in vaccine access.
News: The fight to manufacture COVID vaccines in lower-income countries
Hosted on Acast. See acast.com/privacy for more information.